Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia

Completed · Phase 1 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.

Key facts

Study ID

NCT00876304

Run by

Taisho Pharmaceutical Co., Ltd.

People needed

39

Starts

2009-04-01

Expected to finish

2009-09-01

Last updated by the study team

2010-03-19

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females of non-childbearing capacity aged 18 to 55 years inclusive
• DSM-IV diagnosis of schizophrenia, stable symptoms for at least 3 months
• Body mass index in the range of 18 to 40 kg/m2 and body weight>45 kg.

You may not qualify if…

• Evidence or history of a primary DSM IV axis I diagnosis other than schizophrenia.
• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
• Any condition possibly affecting drug absorption (eg, gastrectomy).

Where it is running

• Pfizer Investigational Site — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.